Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + pemetrexed + tivantinib
- Development stage
- Phase 2
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin, pemetrexed, and tivantinib. Tivantinib is a selective non-ATP competitive oral inhibitor of the MET receptor, while carboplatin and pemetrexed are established chemotherapy agents. Preclinical data showed that MET inhibition blocks tumor cell growth and migration in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). This combination was investigated as a first-line treatment for patients with advanced non-squamous NSCLC or MPM.
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on carboplatin + pemetrexed + tivantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + pemetrexed + tivantinib.